Inhaled therapy for stable chronic obstructive pulmonary disease

Bibliography

• NATIONAL COLLABORATINGCENTRE FOR CHRONIC CONDITIONS: Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax (2004) 59(Suppl. 1):1-232.
   Google Scholar
• VINCKEN W: Bronchodilator treatment of stable COPD: long-acting anticholinergics. Eur. Respir. Rev. (2005) 14(94):23-31.
   Google Scholar
• O'DONNELL DE, LAM MIU, WEBB KA: Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (1999) 160(2):542-549.
   PubMed Web of Science ®Google Scholar
• DISSE B, REICHL R, SPECK G et al.: Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. (1993) 52(5-6):537-544.
   PubMed Web of Science ®Google Scholar
• GROSS NJ: Tiotropium Bromide. Chest (2004) 126(6):1946-1953.
   PubMed Web of Science ®Google Scholar
• VAN NOORD JA, SMEETS JJ, CUSTERS FL, KORDUCKI L, CORNELISSEN PJ: Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur. Respir. J. (2002) 19(4):639-644.
   PubMed Web of Science ®Google Scholar
• CASABURI R, MAHLER DA, JONES PW et al.: A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. (2002) 19(2):217-224.
   PubMed Web of Science ®Google Scholar
• VINCKEN W, VAN NOORD JA, GREEFHORST AP et al.: Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. (2002) 19(2):209-216.
   PubMed Web of Science ®Google Scholar
• MULLER RA, MORRIS DE: Geomagnetic reversals driven by sudden climate changes. Eos (1989) 70:276.
   Google Scholar
• SZAFRANSKI W, CUKIER A, RAMIREZ A et al.: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. (2003) 21(1):74-81.
   PubMed Web of Science ®Google Scholar
• DOUGHERTY JA, DIDUR BL, ABOUSSOUAN LS: Long-acting inhaled β2-agonists for stable COPD. Ann. Pharmacother. (2003) 37(9):1247-1255.
   PubMed Web of Science ®Google Scholar
• JOHNSON M, RENNARD S: Alternative mechanisms for long-acting β(2)-adrenergic agonists in COPD. Chest (2001) 120(1):258-270.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M, DAHL R: Inhaled combination therapy with long-acting β2-agonists and corticosteroids in stable COPD. Chest (2004) 126(1):220-237.
   PubMed Web of Science ®Google Scholar
• DOWLING RB, JOHNSON M, COLE PJ, WILSON R: Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur. Respir. J. (1998) 11(1):86-90.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M, MATERA MG, SANTANGELO G et al.: Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir. Med. (1995) 89(5):357-362.
   PubMed Web of Science ®Google Scholar
• KOTTAKIS J, CIOPPA GD, CREEMERS J et al.: Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can. Respir. J. (2002) 9(2):107-115.
   PubMedGoogle Scholar
• CELIK G, KAYACAN O, BEDER S, DURMAZ G: Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration (1999) 66(5):434-439.
   PubMed Web of Science ®Google Scholar
• CALVERLEY P, PAUWELS R, VESTBO J et al.: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 361(9356):449-456.
   PubMed Web of Science ®Google Scholar
• MAHLER DA, WIRE P, HORSTMAN D et al.: Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2002) 166(8):1084-1091.
   PubMed Web of Science ®Google Scholar
• CALVERLEY PM, BOONSAWAT W, CSEKE Z et al.: Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. (2003) 22(6):912-919.
   PubMed Web of Science ®Google Scholar
• APPLETON S, POOLE P, SMITH B, VEALE A, BARA A: Long-acting β2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst. Rev. (2002) 3:CD001104.
   Google Scholar
• HUSEREAU D, SHUKLA V, BOUCHER M, MENSINKAI S, DALES R: Long acting β2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials. BMC Pulm. Med. (2004) 4(1):7.
   PubMedGoogle Scholar
• DAHL R, GREENFHORST LA, NOWAK D et al.: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2001) 164(5):778-784.
   PubMed Web of Science ®Google Scholar
• CURRIE GP: Indacaterol Novartis/skyePharma. Curr. Opin. Investig. Drugs. (2006) 7(5):457-463.
   PubMed Web of Science ®Google Scholar
• ULRIK CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax (1995) 50(7):750-754.
   PubMed Web of Science ®Google Scholar
• BOYD G, MORICE AH, POUNSFORD JC, SIEBERT M, PESLIS N, CRAWFORD C: An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. (1997) 10(4):815-821. Erratum in (1997) 10(7):1696.
   PubMed Web of Science ®Google Scholar
• CAZZOLA M, MATERA MG, SANTANGELO G, VINCIGUERRA A, ROSSI F, D'AMATO G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a doseresponse study. Respir. Med. (1995) 89(5):357-362.
   PubMed Web of Science ®Google Scholar
• ROSSI A, KRISTUFEK P, LEVINE BE et al.: Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest (2002)121(4):1058-1069.
   PubMed Web of Science ®Google Scholar
• CURRIE GP, LIPWORTH BJ: Pharmacological management--inhaled treatment. Br. Med. J. (2006) 332(7555):1439-1441.
   PubMedGoogle Scholar
• BRUSASCO V, HODDER R, MIRAVITLLES M et al.: Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax (2003) 58(5):399-404.
   PubMed Web of Science ®Google Scholar
• VAN NOORD JA, AUMANN JL, JANSSENS E et al.: Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. (2005) 26(2):214-222.
   PubMed Web of Science ®Google Scholar
• KEATINGS VM, COLLINS PD, SCOTT DM, BARNES PJ: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. (1996) 153(2):530-534.
   PubMed Web of Science ®Google Scholar
• KEATINGS VM, JATAKANON A, WORSDELL YM, BARNES PJ: Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med. (1997) 155(2):542-548.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br. J. Pharmacol. (2006) 148(3):245-254.
   PubMed Web of Science ®Google Scholar
• SIN DD, LACY P, YORK E, MAN SF: Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2004) 170(7):760-765.
   PubMed Web of Science ®Google Scholar
• VERHOEVEN GT, HEGMANS JP, MULDER PG et al.: Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax (2002) 57(8):694-700.
   PubMed Web of Science ®Google Scholar
• ITO K, ITO M, ELLIOTT WM et al.: Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. (2005) 352(19):1967-1976.
   PubMed Web of Science ®Google Scholar
• MAN SFP, SIN DD: Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc. Am. Thorac Soc. (2005) 2(1):78-82.
   PubMedGoogle Scholar
• SIN DD, LACY P, YORK E, MAN SFP: Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2004) 170(7):760-765.
   PubMed Web of Science ®Google Scholar
• LUNG HEALTH STUDY RESEARCHGROUP: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. (2000) 343(26):1902-1909.
   PubMed Web of Science ®Google Scholar
• BURGE PS, CALVERLEY PM, JONES PW et al.: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. (2000) 320(7245):1297-1303.
   PubMed Web of Science ®Google Scholar
• PAUWELS RA, LOFDAHL CG, LAITINEN LA et al.: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. (1999) 340(25):1948-1953.
   PubMed Web of Science ®Google Scholar
• VESTBO J, SORENSEN T, LANGE P et al.: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (1999) 353(9167):1819-1823.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND ER, ALLMERS H, AYAS NT, VENN AJ, MARTIN RJ: Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax (2003) 58(11):937-941.
   PubMed Web of Science ®Google Scholar
• BOURBEAU J, ROULEAU MY, BOUCHER S: Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax (1998) 53(6):477-482.
   PubMed Web of Science ®Google Scholar
• O’DONNELL D, SCIURBA F, CELLI B, MAHLER DA, WEBB KA, KALBERG CJ, KNOBIL K: Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest (2006): 130: 647-656.
   PubMed Web of Science ®Google Scholar
• PAGGIARO PL, DAHLE R, BAKRAN I et al.: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet (1998) 351(9105):773-780.
   PubMed Web of Science ®Google Scholar
• CALVERLEY PMA, SPENCER S, WILLITS L, BURGE PS, JONES PW: Withdrawal from treatment as an outcome in the ISOLDE Study of COPD. Chest (2003) 124(4):1350-1356.
   PubMed Web of Science ®Google Scholar
• GARTLEHNER G, HANSEN RA, CARSON SS, LOHR KN: Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-Analysis of health outcomes. Ann. Fam. Med. (2006) 4(3):253-262.
   PubMed Web of Science ®Google Scholar
• SPENCER S, CALVERLEY PM, SHERWOOD BURGE P, JONES PW: Health status deterioration in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2001) 163(1):122-128.
   PubMed Web of Science ®Google Scholar
• SIN DD, WU L, ANDERSON JA et al.: Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax (2005) 60(12):992-997.
   PubMed Web of Science ®Google Scholar
• DE VRIES F, VAN STAA TP, BRACKE MS et al.: Severity of obstructive airway disease and risk of osteoporotic fracture. Eur. Respir. J. (2005) 25(5):879-884.
   PubMed Web of Science ®Google Scholar
• TOEWS ML, BYLUND DB: Pharmacologic principles for combination therapy. Proc. Am. Thorac Soc. (2005) 2(4):282-289; discussion 290-281.
   PubMedGoogle Scholar
• In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest (1994) 105(5):1411-1419.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN M, SERBY CW, MENJOGE SS et al.: Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared With ipratropium alone and albuterol alone in COPD. Chest (1999) 115(3):635-641.
   PubMed Web of Science ®Google Scholar
• GRASSI V, BRUNI B, PECCINI F, TANTUCCI C, TODISCO T: Acute on chronic comparative effects of a combination of fenoterol-ipratropium bromide and terbutaline in patients with chronic obstructive lung disease. Respiration (1986) 50 (Suppl. 2):226-231.
   PubMedGoogle Scholar
• EICKELBERG O, ROTH M, LORX R et al.: Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. (1999) 274(2):1005-1010.
   PubMed Web of Science ®Google Scholar
• BARNES NC, QIU Y-S, PAVORD ID et al.: Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. (2006) 173(7):736-743.
   PubMed Web of Science ®Google Scholar
• Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. Chest (1997) 112(6):1514-1521.
   PubMed Web of Science ®Google Scholar
• MELANI AS, DI GREGORIO A: Four-week nebulized beclomethasone dipropionate in stable COPD patients with exertional dyspnoea. Monaldi Arch. Chest Dis. (1999) 54(3):224-227.
   PubMedGoogle Scholar